Sofia Santos is a translational scientist with over ten years of experience bridging cancer biology and radiopharmaceutical development. Her work focuses on advancing imaging and therapeutic candidates from early discovery to first-in-human studies.
She completed her PhD in Oncology at the Faculty of Medicine, University of São Paulo, including a two-year collaborative placement at the University of Oxford, where she investigated the molecular mechanisms underpinning tumour angiogenesis and chemotherapy resistance.
She subsequently held a postdoctoral position at the Nuclear and Energy Research Institute (IPEN), leading biological evaluation programmes spanning PET and SPECT modalities.
In 2017, Sofia co-founded a radiopharmaceutical research and consulting company, where she secured over US$970,000 in competitive research funding as principal investigator from the São Paulo Research Foundation (FAPESP).
She later relocated to the UK to join King’s College London as a Postdoctoral Research Fellow, focusing on the preclinical evaluation and translational development of radiopharmaceuticals for cancer imaging and therapy.
During this time, she played a central role in generating the preclinical evidence supporting ALDH1A1 as a druggable biomarker and advancing NTx-011 as Nuclide Therapeutics’ lead theranostic candidate.
Her research has resulted in over 35 peer-reviewed publications and five book chapters.
At Nuclide Therapeutics, she leads operations and oversees the company’s translational and clinical development strategy, guiding programmes from laboratory validation through to clinical readiness.
